OGEN

Company Overview — What Does ORAGENICS INC Do?

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. ORAGENICS INC (OGEN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kimberly M. Murphy and employs approximately 5 people, headquartered in TAMPA, Florida. With a market capitalization of $2M, OGEN is one of the notable companies in the Healthcare sector.

ORAGENICS INC (OGEN) Stock Rating — Avoid (April 2026)

As of April 2026, ORAGENICS INC receives a Avoid rating with a composite score of 22.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.OGEN ranks #4,249 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ORAGENICS INC ranks #767 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OGEN Stock Price and 52-Week Range

ORAGENICS INC (OGEN) currently trades at $0.60. The stock lost $0.02 (2.7%) in the most recent trading session. The 52-week high for OGEN is $7.60, which means the stock is currently trading -92.1% from its annual peak. The 52-week low is $0.11, putting the stock 448.2% above its annual trough. Recent trading volume was 21K shares, suggesting relatively thin trading activity.

Is OGEN Overvalued or Undervalued? — Valuation Analysis

ORAGENICS INC (OGEN) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.30x, versus the sector average of 2.75x.

At current multiples, ORAGENICS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ORAGENICS INC Profitability — ROE, Margins, and Quality Score

ORAGENICS INC (OGEN) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -118.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -97.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OGEN Debt, Balance Sheet, and Financial Health

ORAGENICS INC has a debt-to-equity ratio of 22.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.64x, indicating strong short-term liquidity. Total debt on the balance sheet is $394,836. Cash and equivalents stand at $11M.

OGEN has a beta of 4.78, meaning it is more volatile than the broader market — a $10,000 investment in OGEN would be expected to move 377.7% more than the S&P 500 on any given day. The stability factor score for ORAGENICS INC is 7/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ORAGENICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, ORAGENICS INC reported revenue of $0 and earnings per share (EPS) of $-4.56. Net income for the quarter was $-10M. Operating income came in at $-9M.

In FY 2025, ORAGENICS INC reported revenue of $0 and earnings per share (EPS) of $-4.56. Net income for the quarter was $-10M. Operating income came in at $-9M.

In Q3 2025, ORAGENICS INC reported revenue of $0 and earnings per share (EPS) of $-1.96. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, ORAGENICS INC reported revenue of $0 and earnings per share (EPS) of $-3.10. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, ORAGENICS INC has experienced revenue contraction from $0 to $0. Investors analyzing OGEN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OGEN Dividend Yield and Income Analysis

ORAGENICS INC (OGEN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OGEN Momentum and Technical Analysis Profile

ORAGENICS INC (OGEN) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 22/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

OGEN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ORAGENICS INC (OGEN) ranks #767 out of 838 stocks based on the Blank Capital composite score. This places OGEN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OGEN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OGEN vs S&P 500 (SPY) comparison to assess how ORAGENICS INC stacks up against the broader market across all factor dimensions.

OGEN Next Earnings Date

No upcoming earnings date has been announced for ORAGENICS INC (OGEN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OGEN? — Investment Thesis Summary

The quantitative profile for ORAGENICS INC suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. High volatility (stability score 7/100) increases portfolio risk.

In summary, ORAGENICS INC (OGEN) earns a Avoid rating with a composite score of 22.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OGEN stock.

Related Resources for OGEN Investors

Explore more research and tools: OGEN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OGEN head-to-head with peers: OGEN vs AZN, OGEN vs SLGL, OGEN vs VMD.